The European ph III study for MOB-015 showed a similar top-line result as the North American study. The primary endpoint was met but the complete cure rate was low at only 1.8%. The mycological cure rate was, however, high at 84%. The result clouds the way to market even though it can be enough for product registration in Europe. A new study (with a shortened dosing regimen) has already been planned to meet the formal requirement for registration in the US. Marketing material commissioned by Moberg Pharma.

equityresearch@nordea.com

Nordea Research